Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. (Nasdaq: INTS) is a late-stage clinical biotechnology company focused on proprietary, immune-based intratumoral cancer therapies. News about Intensity centers on the clinical development of its lead investigational product candidate, INT230-6, corporate milestones, capital raises, and interactions with regulators and the Nasdaq Capital Market.
Company press releases frequently highlight progress in key clinical programs. These include the Phase 3 INVINCIBLE-3 study in specific soft tissue sarcoma subtypes, where INT230-6 is tested as second- or third-line monotherapy against standard-of-care drugs, and the Phase 2 INVINCIBLE-4 study in presurgical triple-negative breast cancer, which evaluates INT230-6 followed by standard-of-care immunochemotherapy versus standard of care alone with pathological complete response as the primary endpoint. Updates have covered enrollment status, dosing regimen adjustments, early safety observations, and notable findings such as a pathological complete response in the first evaluated patient in the INT230-6 cohort of INVINCIBLE-4.
News flow also includes scientific and medical communications, such as publication of the IT-01 Phase 1/2 study results in eBioMedicine, a Lancet Discovery Science journal, and presentations or posters at major oncology meetings like the San Antonio Breast Cancer Symposium. These items describe disease control rates, overall survival data, abscopal effects, immune activation, and pharmacokinetic findings for INT230-6 in advanced solid tumors.
Investors following INTS can also expect announcements on financial results, registered direct offerings, at-the-market equity sales, and updates on cash runway. Additional disclosures cover Nasdaq listing matters, including extensions to regain compliance with minimum bid price rules and stockholder votes on potential reverse stock splits. For those tracking Intensity Therapeutics, this news page provides a centralized view of clinical, scientific, financial, and regulatory developments related to the company and its intratumoral oncology pipeline.
Intensity Therapeutics presented promising results from the INVINCIBLE study at the San Antonio Breast Cancer Symposium. In this Phase 2 trial, the drug INT230-6 achieved up to 100% tumor necrosis in patients with early-stage breast cancer, demonstrating significant immune response activation. The study involved 91 participants and highlighted INT230-6's potential as a pre-surgical treatment with manageable adverse effects. The data is bound to impact future cancer therapy approaches and reinforces the company's pioneering position in immune-based cancer treatments.
Intensity Therapeutics announced data from its ongoing Phase 1/2 study of INT230-6 presented at the CTOS Annual Meeting. Preliminary findings indicate that administering INT230-6 either alone or in combination with ipilimumab improves median overall survival (mOS) in patients with refractory sarcomas. Patients receiving a cumulative dose equivalent to 40% or more of their tumor burden exhibited an mOS of 715 days, compared to historical controls at 205 days. The results suggest favorable safety, supporting the potential of INT230-6 in treating metastatic sarcomas.
Intensity Therapeutics announced promising results from its phase 1/2 trial involving the cancer treatment INT230-6. Patients receiving INT230-6 alone had a median overall survival (mOS) of 373 days, significantly longer compared to historical data. In combination with pembrolizumab, the mOS was 205 days in a heavily pretreated patient group. The treatment has shown good tolerability and efficacy, inducing both tumor cell death and immune activation. Results will be presented at the SITC Annual Meeting, indicating ongoing research towards potential commercialization.
Intensity Therapeutics announced positive data from the INVINCIBLE study, showcasing significant tumor necrosis in early-stage breast cancers resistant to chemotherapy. The trial utilized INT230-6, which demonstrated up to 100% necrosis from a single injection, alongside increased immune cell activity in the tumor microenvironment. No surgical procedures were canceled or delayed due to the treatment. Results will be presented at the 2022 SITC Annual Meeting, indicating INT230-6's potential to alter treatment paradigms for patients awaiting surgery.
FAQ
What is the current stock price of INTENSITY THERAPEUTICS (INTS)?
What is the market cap of INTENSITY THERAPEUTICS (INTS)?
